This document discusses the role of aromatase inhibitors (AIs) in assisted reproductive technologies. It addresses several key questions: 1. Whether the addition of AIs increases pregnancy rates, which needs further evidence. 2. That the addition of AIs does reduce costs by decreasing the amount of gonadotropins needed. 3. Whether the addition of AIs augments ovarian response, which also needs more evidence. The document provides background on AIs and their pharmacology. It reviews studies on the use of letrozole in ovarian stimulation protocols and outcomes like pregnancy rates, cost savings, and safety.